Biopharmaceutical firm Celgene is set to apply to the US Food and Drug Administration for approval of its CAR-T liso-cel treatment for lymphoma during Q2 and for its CAR-T ide-cel therapy for multiple myeloma during Q1 2020, the company revealed in its Q4 earnings report. Trials for the liso-cel therapy saw four out of six patients with secondary central nervous system lymphoma achieve complete responses, while 2017 data showed that 68 patients achieved a 75% response rate and 56% of patients had a complete response rate.
Biopharmaceutical firm Celgene is set to apply to the US Food and Drug Administration for approval of its CAR-T liso-cel treatment for lymphoma during Q4 and for its CAR-T ide-cel therapy for multiple myeloma during Q1 2020, the company revealed in its Q2 earnings report. Trials for the liso-cel therapy saw four out of six patients with secondary central nervous system lymphoma achieve complete responses, while 2017 data showed that 68 patients achieved a 75% response rate and 56% of patients had a complete response rate.